Clin2
NCT07601074Possibly a fitRecruiting

Testing DARE-HPV to Clear Persistent HPV Infection

Human Papilloma Virus (HPV)High-risk Human Papillomavirus Infection

Treatments studied

Part of Infections clinical trials.

This study tests whether DARE-HPV, a new treatment, can help your body clear a persistent human papillomavirus (HPV) infection that hasn't gone away on its own. HPV is a common virus; persistent infection with certain high-risk types can lead to cervical cancer, so clearing it early may prevent future problems.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
118 people
Ages
22 years to 50 years
Study type
Interventional

Who can take part

  • You are a premenopausal woman aged 22–50 years old
  • You have tested positive for high-risk HPV at least twice over 12+ months (showing the infection persists)
  • You have no serious medical conditions and are generally in good health
  • You are not pregnant, breastfeeding, or planning to become pregnant during the study
  • You can commit to avoiding vaginal intercourse, douching, tampons, and condoms for specific periods around treatment
  • You do not have active vaginal infections (gonorrhea, chlamydia, bacterial vaginosis, yeast, or trichomoniasis) or HIV/hepatitis

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05829629Recruiting· Phase 1
Test of an HPV vaccine-like treatment for HPV16 in women

This Phase 1 study tests FluBHPVE6E7, a new treatment designed to help the immune system respond to HPV16. It mainly checks safety and the best dose, and may help your body clear or control HPV over time.

Bratislava
NCT04232917Recruiting· Phase 4
Testing a treatment to help clear genital high-risk HPV

This trial studies 2LPAPI® to see if it helps the body clear high-risk HPV infections in the cervix. It may be an option if you have a current HPV infection with mild/early abnormal cervical findings and can complete follow-up for about a year.

Brussels
NCT07431502Not yet recruiting· Phase 3
HPV vaccine to prevent precancerous lesions from returning

This trial tests whether an HPV vaccine (the nonavalent type) can help prevent the same precancerous lesions from coming back after treatment. It is for people who currently have a high-grade HPV-related lesion but have not yet been treated for it.

NCT07536282Not yet recruiting· Phase 1/Phase 2
Testing NWRD09 for persistent HPV16 infection in women

This study tests a new treatment called NWRD09 for women with a long-lasting HPV16 infection that shows concerning cell changes in the cervix. The goal is to see if this treatment can help your immune system clear the infection and prevent it from developing into cervical cancer.

New York, New York
NCT07710703Recruiting
Study of NWRD09 for persistent HPV 16 infection in women

This trial tests an experimental treatment called NWRD09 for women who have had a persistent HPV 16 infection for at least 12 months. The goal is to see if it can clear the virus and prevent cervical changes.

Beijing
NCT03913117Recruiting· Phase 1
Test treatment for HPV16-positive mild abnormal cervical cell results

This early (Phase 1) study tests a new treatment for people with long-lasting mild abnormal Pap test results (ASC-US or LSIL) who also have HPV16 found on testing. It aims to find out whether the treatment can be given safely and may affect the HPV and abnormal cell changes.

Birmingham, Alabama

Hear when a new Human Papilloma Virus (HPV) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.